Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound for modulating kinase activity of Formula I,

or a pharmaceutically acceptable salt thereof, wherein,

Ar is selected from the following formulae

$$N$$
 N $(R^1)_{0-3}$ $(R^1)_{0-3}$

wherein Ar is substituted with -X and -Y-L-Z, in an ortho relationship to each other, and said Ar is optionally substituted with up to four R^1 ;

each R^1 is independently selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R³, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, -OC(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower heterocyclylalkyl;

X is selected from the following formulae.

wherein R^{4a} is $-C(O)N(R^3)R^3$;

n = 1 or 2;

p = 0 or 1;

q is 1 to 3;

M is $-OR^3$ or $-N(R^3)R^4$;

each R^2 is independently selected from -H, halogen, oxo, -CN, -NH₂, -NO₂, -OR³, -N(R³)R³, -N(R³)R⁵, -S(O)_{0.2}R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)C(O)R³, -OC(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower heterocyclyl, and optionally substituted lower heterocyclylalkyl;

two of R², together with the atoms to which they are attached, can form an optionally substituted three-to seven-membered ring system;


each R^2 is independently selected from -H, haloalkyl, $-C_{1-6}$ alkyl- $N(R^3)R^3$, $-C_{1-6}$ alkyl- CO_2R^3 , and $-C_{1-6}$ alkyl- $C(O)N(R^3)R^3$;

each R³ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of R³, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;

each R^4 is independently selected from R^3 , $-SO_2R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, and $-C(O)R^3$;

-Y-L-Z is selected from the following formulae,



3

McDonnell Boehnen Hulbert & Berghoff LLP

August 6, 2010, Office Action Response Application No. 10/549,300 Attorney Docket No. EX04-018C-US (05-934-F)

Y-L-Z is selected from the following formulae,

wherein g is zero to two; D is selected from $-C(R^5)(R^5)$, -O, $S(O)_{0.2}$, and $N(R^4)$; Q is =N or $-C(R^5)$, T is selected from absent, $-N(R^3)$ -, -S- and -O-; and each methylene between Y and T is optionally substituted; provided that when both Y and T are heteroatoms then g must be two;

Y is selected from -CH₂-, -O-, -S(O)₀₋₂-, -N(R³)-, and absent;

Y is -O- or optionally substituted -CH₂-;

 R^5 is selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R⁴, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

optionally two of R⁵, together with the atoms to which they are attached, form a second ring system fused with said five- to seven-membered ring system, said second ring system substituted with zero to four of R⁵.

- 2. (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Canceled)
- 9. (Canceled)

- 10. (Canceled)
- 11. (Canceled)
- 12. (Currently amended) The compound according to claim—11_1, wherein g is one or two.
- 13. (Original) The compound according to claim 12, wherein each R^5 is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR³, -N(R³)R⁴, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, and optionally substituted lower alkyl.
- 14. (Original) The compound according to claim 13, wherein -Y-L-Z is selected from the following formulae.

$$R^{3}$$
 R^{4b} R^{3} R^{4b} R^{3} R^{4b} R^{5} R

15. (Currently amended) The compound according to claim 14, having formula III,

$$R^{3a}$$
 O R^{5} O R^{3b} R^{4b} R^{4b} R^{4b} R^{4b}

Ш

wherein J is N or CH, and B is =N- or = $C(R^5)$ -.

- 16. (Original) The compound according to claim 15, wherein R^{3a} is selected from optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl.
- 17. (Original) The compound according to claim 16, wherein R^{3a} is selected from optionally substituted aryl and optionally substituted heteroaryl.

- 18. (Original) The compound according to claim 17, wherein R^{3a} is optionally substituted phenyl.
- 19. (Original) The compound according to claim 18, wherein said optionally substituted phenyl is substituted with at least one of halogen, -CN, -CF₃, -NH₂, -NO₂, -OR³, -N(R³)R³, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, and optionally substituted aryl.
- 20. (Original) The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one trifluoromethyl group.
- 21. (Original) The compound according to claim 20, wherein said optionally substituted phenyl group is substituted with at least two trifluoromethyl groups
- 22. (Original) The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one lower alkyl group.
- 23. (Original) The compound according to claim 19, wherein R^{3b} is -H.
- 24. (Original) The compound according to claim 23, wherein R^{4b} is selected from R^3 , -H, $-CO_2R^3$, $-C(O)N(R^3)R^4$, and $-C(O)R^3$.
- 25. (Canceled)
- 26. (Canceled)
- 27. (Original) The compound according to claim 24, wherein Ar is according to the formula below.

28. (Original) The compound according to claim 24, wherein Ar is according to the formula below.



- 29. (Canceled)
- 30. (Previously presented) A compound for modulating kinase activity of Formula IV,

or a pharmaceutically acceptable salt thereof, wherein,

Ar is selected from the following formulae:

$$N$$
 N $(R^1)_{0-3}$ $(R^1)_{0-3}$

each R^1 is independently selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R³, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; optionally two of R¹, together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of R¹;

each R^2 is independently selected from -H, halogen, oxo, -CN, -NH₂, -NO₂, -OR³, -N(R³)R³, -N(R³)R⁵, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³,

 $-N(R^3)CO_2R^3$, $-N(R^3)C(O)N(R^3)R^3$, $-C(O)R^3$, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

two of R², together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;

each R³ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of R³, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;

each R^4 is independently selected from R^3 , $-SO_2R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, and $-C(O)R^3$;

Y is selected from optionally substituted -CH₂-, -O-, -S-, and -N(R³)-;

L is selected from optionally substituted -CH₂-, -O-, -S-, -N(\mathbb{R}^3)- and absent;

provided that Y and L are not both heteroatoms;

B is =N- or =C(H)-;

at each instance, R^5 and R^6 are independently selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R⁴, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower heterocyclylalkyl; and

optionally two of R⁵, together with the atoms to which they are attached, form a ring system fused with the ring containing B according to formula **IV**, said ring system substituted with zero to two additional of R⁵.

- 31. (Original) The compound according to claim 30, wherein Y is -O- and L is optionally substituted -CH₂-.
- 32. (Original) The compound according to claim 31, wherein at least one of R⁶ is optionally substituted lower alkyl.
- 33. (Original) The compound according to claim 32, wherein said at least one optionally substituted lower alkyl is *meta* to the piperazine urea function as depicted in formula **IV**.
- 34. (Original) The compound according to claim 33, wherein R^{4a} is selected from R^3 , -H, $-CO_2R^3$, $-C(O)N(R^3)R^4$, and $-C(O)R^3$.
- 35. (Original) The compound according to claim 34, wherein R^{4a} is selected from -H, $-CO_2R^3$, $-C(O)N(R^3)R^4$, and $-C(O)R^3$.
- 36. (Original) The compound according to claim 35, wherein -Y-L- is -OCH₂-.
- 37. (Canceled)
- 38. (Canceled)
- 39. (Original) The compound according to claim 36, wherein Ar is according to the formula below.

40. (Original) The compound according to claim 36, wherein Ar is according to the formula below.



- 41. (Canceled)
- 42. A compound selected from Table 4.

Table 4

Table 4

97	N-[3,5-bis(trifluoromethyl)phenyl]-4- {3-[(pyridin-4-ylmethyl)oxy]pyridin-2- yl}piperazine-1-carboxamide	F_3C CF_3 N
103	N-(4-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide	$\left\langle \begin{array}{c} z \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $
105	N-(3-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-1-carboxamide	
142	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N
144	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	NH ₂
161	methyl [4-({[2-(4-{[(3-ethylphenyl)amino]carbonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]carbamate	

Table 4

164	methyl [4-({[2-(4-{[(3-bromophenyl)amino]carbonyl}piperazin -1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]carbamate	NH NN NH NH
165	methyl {4-[({2-[4-({[3-(methyloxy)phenyl]amino}carbonyl)piperazin-1-yl]pyridin-3-yl}oxy)methyl]pyridin-2-yl}carbamate	
166	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-(methyloxy)phenyl]piperazine-1-carboxamide	NH ₂ N N N N N N N N N N N N N N N N N N N
167	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-(1-methylethyl)phenyl]piperazine-1-carboxamide	NH ₂ N N N N N N N N N N N N N N N N N N N
168	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-{3-[(trifluoromethyl)oxy]phenyl}piperazine -1-carboxamide	NH ₂ N N N N N N N N N N N N N N N N N N N
169	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[2-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	NH ₂ N F ₃ C F

Table 4

	,	
170	N-(3-ethylphenyl)-4-[3-({[2-({[(3-ethylphenyl)amino]carbonyl}amino)pyridin-4-yl]methyl}oxy)pyridin-2-yl]piperazine-1-carboxamide	HN NH NH NH NH
171	N-(3-ethylphenyl)-4-(3-{[(2-{[(4- methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	NH NH NH
173	N-[3,5-bis(trifluoromethyl)phenyl]-4-(3- {[(2-{[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	$\begin{array}{c c} & & & & \\ & & & & \\ & & & & \\ & & & &$
174	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N
175	4-[3-({[2-(acetylamino)pyridin-4-yl]methyl}oxy)pyridin-2-yl]-N-(3-ethylphenyl)piperazine-1-carboxamide	NH NH NH

Table 4

176	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethyl-4-fluorophenyl)piperazine-1-	H_2N N N N N N N N
	carboxamide	` <u></u> / / <u>}_/</u> F
177	2-[4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)piperazin-1-yl]-N-[3,5-bis(trifluoromethyl)phenyl]acetamide	N N N NH ₂ F ₃ C CF ₃
178	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-phenylpiperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
179	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-chloro-5-ethylphenyl)piperazine-1-carboxamide	H ₂ N NH NH CI
180	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(5-ethyl-2-fluorophenyl)piperazine-1-carboxamide	H_2N N N N N N N N N N
181	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-bromo-5-ethylphenyl)piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N

Table 4

	Table 4	
182	2-(4-methylpiperazin-1-yl)ethyl [4-({[2-(4-{[(3-ethylphenyl)amino]carbonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]carbamate	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
183	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-chlorophenyl)piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
184	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-bromophenyl)piperazine-1-carboxamide	H ₂ N N N NH NH Br
185	N-[4-({[2-(4-acetylpiperazin-1-yl)pyridin-3-yl]oxy}methyl)pyridin-2-yl]-2-(4-methylpiperazin-1-yl)acetamide	HN N
186	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-fluorophenyl)piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
187	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(4-fluorophenyl)piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N

Table 4

	1 able 4	
188	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(2-fluorophenyl)piperazine-1-carboxamide	H_2N N N N N N N N N N
189	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3,5-diethylphenyl)piperazine-1-carboxamide	H ₂ N NH NH
190	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-5-bromopyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	Br N N N N N N N N N N N N N N N N N N N
191	N-methyl-4-(3-{[(2-{[(4- methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N
192	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[2-chloro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N
193	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(5-chloro-2-fluorophenyl)piperazine-1-carboxamide	H_2N N N N N N N N N N
194	4-(3-{[(2-amino-5-bromopyrimidin-4-yl)methyl]oxy}-5-bromopyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	Br N N N N N N N N N N N N N N N N N N N

Table 4

195	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[2-fluoro-3-(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N
196	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	H ₂ N N CF ₃
197	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3,5-dichlorophenyl)piperazine-1-carboxamide	H_2N N N N N N N N N N
198	N-(3-chloro-5-ethylphenyl)-4-(3-{[(2- {[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	CI NH NH NH NH NH NH NH NH NH NH
199	N-(5-ethyl-2-fluorophenyl)-4-(3-{[(2- {[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	NH NH NH

Table 4

	1 able 4	
200	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-ethyl-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
204	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-methylpiperazine-1-carboxamide	H ₂ N NH NH
205	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-ethylpiperazine-1-carboxamide	H ₂ N NH
206	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-cyclohexylpiperazine-1-carboxamide	H_2N N N N N N N N
207	4-({[2-(4-acetylpiperazin-1-yl)pyridin-3-yl]oxy}methyl)pyrimidin-2-amine	N N N N N N N N N N N N N N N N N N N
208	4-({[2-(4-propanoylpiperazin-1-yl)pyridin-3-yl]oxy}methyl)pyrimidin-2-amine	N N N N N N N N N N N N N N N N N N N
209	N-(3-cyclopropylphenyl)-4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl]oxy}pyridin-2-yl)piperazine-1-carboxamide	NH NH NH

Table 4

210	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-cyclopropylphenyl)piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
211	N-[2-fluoro-5-(trifluoromethyl)phenyl]- 4-(3-{[(2-{[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	$\begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$
212	N-[3-fluoro-5-(trifluoromethyl)phenyl]- 4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	F S S S S S S S S S S S S S S S S S S S
213	N-(3,5-dichlorophenyl)-4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl]oxy}pyridin-2-yl)piperazine-1-carboxamide	CI NEW TOTAL CITY OF THE PROPERTY OF THE PROP
214	4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]piperazine-1-carboxamide	N N N N N N N N N N

Table 4

216	4-(3-{[1-(2-aminopyrimidin-4-yl)ethyl]oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N
219	4-[({2-[4-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperazin-1-yl]pyridin-3-yl}oxy)methyl]pyrimidin-2-amine	N N NH ₂
220	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(2-methylpropyl)piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
226	N-(3,5-diethylphenyl)-4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)oxy]methyl}pyridin-2-yl)piperazine-1-carboxamide	NH NH NH
227	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-methylpyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	H ₂ N NH NH
228	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-methylpyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N

Table 4

233	N-[3-chloro-5-(trifluoromethyl)phenyl]- 4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N
235	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-chloro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N
237	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-chloropyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	CI N N NH NH
243	N-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-4-(3-{[(2-{[(4- methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	R R R R R R R R R R
244	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-chloropyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N

Table 4

245	4-(3-{[1-(2-aminopyrimidin-4-yl)ethyl]oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	H ₂ N N N N NH NH
246	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-chloropyridin-2-yl)-N-(5-ethyl-2-fluorophenyl)piperazine-1-carboxamide	CI N N N N N N N N N N N N N F
247	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethyl-5-fluorophenyl)piperazine-1-carboxamide	H_2N N N N N N N N N N
249	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]piperazine-1-carboxamide	H_2N N N N N N N N N N
250	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]-N-methylpiperazine-1-carboxamide	H_2N N N N N N N N N N

- 43. (Previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
- 44. (Canceled)
- 45. (Canceled)
- 46. (Canceled)
- 47. (Canceled)

- 48. (Canceled)
- 49. (Canceled)
- 50. (Canceled)
- 51. (Canceled)
- 52. (Canceled)
- 53. (Canceled)
- 54. (Canceled)
- 55. (Canceled)
- 56. (Canceled)
- 57. (Canceled)